Company intelligence / Profile preview
Curadim Pharma
Tokyo / Chiyoda-ku, Tokyo-to, Japancuradim.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Curadim Pharma focused on discovering and developing innovative pharmaceutical products for diseases with high unmet medical needs, especially within immunology. Its lead program, CP-1050, entered a Phase 1 clinical trial to assess safety and pharmacokinetics in healthy volunteers. The company is now dissolved/closed as of May 2019; no further clinical results are available or published.
- Therapeutic areas
- ImmunologyOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Curadim Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curadim Pharma.